A Pilot Trial of Nabilone for the Treatment of Obesity

Exclusion Criteria

• •Unstable gastrointestinal, respiratory, endocrinological, cardiovascular or cerebrovascular diseases that would prevent participation in the trial at QI (or its delegate) discretion,
• •Unstable major psychiatric disorder(s) (i.e. Axis I Disorders) that would prevent participation in the trial at QI (or its delegate) discretion,
• •Current substance use disorders (DSM-V) (excluding tobacco and caffeine),
• •History of, or current neurological illnesses, that would prevent participation in the trial,
• •Current use or use during the previous month of antipsychotic medications,
• •Learning disability, amnesia or other conditions that impede memory and attention,
• •Visual impairments that prevent participation in the study,
• •Personal or family history of schizophrenia, or psychosis (or psychosis-related) disorders,
• •Antibiotic use in the last 4 weeks,
• •Previous bariatric surgery,
• •Current use or use in the past month of other weight-loss pharmaceuticals,
• •Cannabis use in last 6 months,
• •Known sensitivity to cannabis or other cannabinoid agents,
• •Pregnancy or lactation (females), and
• •For the optional imaging component of the study:
• •* Presence of metal implants or objects unsafe for MRI such as cardiac pacemakers, metal fragments in the eye, and aneurysm clips in your brain
• •* Piercings or jewelry that are unable to be removed
• •* Tattoos inked with metal dyes